See more : East Africa Metals Inc. (EFRMF) Income Statement Analysis – Financial Results
Complete financial analysis of Genetic Technologies Limited (GTG.AX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Genetic Technologies Limited, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- OmniAb, Inc. (OABIW) Income Statement Analysis – Financial Results
- Silver Viper Minerals Corp. (VIPRF) Income Statement Analysis – Financial Results
- Autek China Inc. (300595.SZ) Income Statement Analysis – Financial Results
- Malin Corporation plc (MLC.IR) Income Statement Analysis – Financial Results
- Up Young Cornerstone Corp. (6728.TWO) Income Statement Analysis – Financial Results
Genetic Technologies Limited (GTG.AX)
About Genetic Technologies Limited
Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates in two segments, EasyDNA and GeneType/Corporate. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, and type 2 diabetes. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.66M | 10.35M | 6.79M | 120.55K | 837.87K | 25.44K | 189.25K | 518.51K | 824.59K | 2.01M | 4.56M | 3.38M | 11.33M | 18.28M | 9.76M | 6.67M | 15.74M | 13.76M | 9.90M | 9.47M | 3.78M | 9.26M | 13.11M | 5.63M | 4.02M |
| Cost of Revenue | 3.76M | 4.34M | 321.22K | 361.03K | 101.43K | 276.27K | 300.09K | 492.42K | 743.06K | 1.33M | 2.92M | 1.95M | 1.95M | 2.03M | 2.72M | 2.73M | 891.43K | 6.56M | 8.07M | 4.61M | 3.19M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.90M | 6.01M | 6.47M | -240.47K | 736.43K | -250.82K | -110.83K | 26.09K | 81.53K | 685.26K | 1.65M | 1.43M | 9.38M | 16.24M | 7.04M | 3.94M | 14.84M | 7.19M | 1.83M | 4.85M | 594.57K | 9.26M | 13.11M | 5.63M | 4.02M |
| Gross Profit Ratio | 50.94% | 58.10% | 95.27% | -199.47% | 87.89% | -985.78% | -58.56% | 5.03% | 9.89% | 34.06% | 36.09% | 42.39% | 82.80% | 88.87% | 72.16% | 59.05% | 94.34% | 52.29% | 18.51% | 51.27% | 15.72% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 752.75K | 1.28M | 705.51K | 3.11M | 865.63K | 2.36M | 2.21M | 2.37M | 2.69M | 2.85M | 3.30M | 3.46M | 4.03M | 4.38M | 90.00K | 927.15K | 1.27M | 4.52M | 3.79M | 2.40M | 2.37M | 1.22M | 1.06M | 300.00K | 0.00 |
| General & Administrative | 10.22M | 1.36M | 2.18M | 4.16M | 2.04M | 3.83M | 3.02M | 3.11M | 3.00M | 4.22M | 3.17M | 6.81M | 6.88M | 7.79M | 9.66M | 13.98M | 10.44M | 0.00 | 0.00 | 0.00 | 0.00 | 1.76M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 2.61M | 2.95M | 1.89M | 1.12M | 279.31K | 576.08K | 1.07M | 2.72M | 3.19M | 4.50M | 6.25M | 5.27M | 4.38M | 3.02M | 340.63K | 337.93K | 222.12K | 0.00 | 0.00 | 0.00 | 0.00 | 348.80K | 224.57K | 473.12K | 0.00 |
| SG&A | 12.83M | 10.80M | 4.07M | 5.28M | 4.38M | 4.41M | 4.08M | 5.83M | 6.19M | 8.73M | 9.42M | 12.08M | 11.26M | 10.81M | 10.00M | 14.31M | 10.66M | 4.23M | 4.21M | 10.23M | 5.88M | 348.80K | 224.57K | 473.12K | 0.00 |
| Other Expenses | -9.67M | 45.72K | -1.49M | 116.27K | -799.45K | 137.27K | 0.00 | 0.00 | 58.00K | 564.82K | -610.11K | 8.00K | 4.88K | 0.00 | 4.63M | 5.13M | 4.86M | 4.23M | 4.21M | 10.23M | 5.88M | 12.02M | 20.70M | 8.76M | 6.82M |
| Operating Expenses | 3.90M | 18.11M | 3.11M | 7.00M | 6.98M | 6.18M | 5.34M | 8.44M | 8.58M | 9.27M | 11.15M | 10.58M | 15.29M | 15.19M | 14.72M | 20.18M | 16.79M | 8.75M | 8.00M | 12.62M | 8.25M | 13.59M | 21.98M | 9.06M | 6.82M |
| Cost & Expenses | 7.66M | 22.45M | 3.43M | 7.36M | 7.08M | 6.46M | 5.64M | 8.93M | 9.32M | 10.60M | 14.07M | 12.52M | 17.24M | 17.23M | 2.72M | 22.91M | 17.68M | 15.31M | 16.07M | 17.24M | 11.44M | 13.59M | 21.98M | 9.06M | 6.82M |
| Interest Income | 119.51K | 190.65K | 36.26K | 62.39K | 49.56K | 5.76K | 13.63K | 6.77K | 38.21K | 224.74K | 628.15K | 217.44K | 609.81K | 200.02K | 211.43K | 21.40K | 142.00 | 455.40K | 811.00K | 635.13K | 504.33K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 51.62K | 29.52K | 15.22K | 14.05K | 14.82K | 20.03K | 28.84K | 32.00K | 28.89K | 264.69K | 744.20K | 38.97K | 45.22K | 81.93K | 100.42K | 110.90K | 66.91K | 61.83K | 85.33K | 41.64K | 0.00 | 0.00 | 10.49K | 12.68K | 0.00 |
| Depreciation & Amortization | 534.89K | 676.58K | 578.67K | 478.22K | 265.93K | 156.25K | 303.75K | 371.61K | 390.07K | 232.20K | 338.45K | 398.31K | 561.94K | 616.87K | 3.71M | 4.94M | 4.77M | 1.71M | 2.39M | 1.49M | 626.72K | 3.48M | 4.09M | 3.47M | 289.92K |
| EBITDA | -11.43M | -11.20M | -7.20M | -7.06M | -5.87M | -6.86M | -5.46M | -7.80M | -8.10M | -8.42M | -9.05M | -8.93M | -4.74M | 1.58M | -5.55M | -4.25M | 1.47M | 158.63K | -4.28M | -6.22M | -7.03M | -841.52K | -2.69M | 35.51K | -2.52M |
| EBITDA Ratio | -149.13% | -96.99% | -54.64% | -5,859.26% | -700.99% | -26,967.46% | -3,223.08% | -1,504.25% | -982.85% | -478.86% | -216.31% | -277.06% | -41.79% | 5.85% | 72.16% | -43.16% | 39.85% | 3.14% | -39.43% | -65.65% | -200.97% | -9.08% | -36.50% | 0.63% | -62.59% |
| Operating Income | -6.54M | -10.42M | -7.54M | -7.42M | -5.94M | -7.02M | -6.40M | -8.17M | -8.49M | -9.87M | -10.21M | -9.11M | -5.91M | 965.55K | -7.68M | -8.24M | -1.95M | -1.56M | -6.17M | -7.77M | -7.66M | -4.33M | -8.88M | -3.43M | -2.81M |
| Operating Income Ratio | -85.29% | -100.66% | -111.03% | -6,156.21% | -708.77% | -27,581.59% | -3,383.58% | -1,575.92% | -1,030.16% | -490.40% | -223.73% | -269.72% | -52.13% | 5.28% | -78.74% | -123.53% | -12.36% | -11.31% | -62.32% | -82.02% | -202.36% | -46.69% | -67.74% | -60.91% | -69.80% |
| Total Other Income/Expenses | -5.48M | -1.49M | -2.35M | 343.94K | -1.90M | 592.26K | 939.68K | -232.58K | 336.12K | 1.06M | 77.18K | -23.22K | 610.24K | -85.77K | 324.82K | 380.01K | -3.52M | 120.06K | 852.54K | 537.03K | 839.40K | 0.00 | -10.49K | -12.68K | -4.30K |
| Income Before Tax | -12.02M | -11.91M | -7.16M | -7.08M | -6.29M | -6.43M | -5.46M | -8.40M | -8.46M | -8.81M | -10.13M | -9.35M | -5.30M | 901.34K | -9.36M | -9.74M | -5.46M | -1.44M | -5.32M | -7.23M | -6.82M | -4.33M | -8.89M | -3.44M | -2.81M |
| Income Before Tax Ratio | -156.78% | -115.09% | -105.42% | -5,870.91% | -751.29% | -25,253.91% | -2,887.06% | -1,620.78% | -1,025.84% | -437.90% | -222.04% | -276.84% | -46.75% | 4.93% | -95.88% | -146.01% | -34.72% | -10.43% | -53.71% | -76.35% | -180.17% | -46.69% | -67.82% | -61.14% | -69.91% |
| Income Tax Expense | 0.00 | 158.33K | -32.13K | -135.43K | -750.00K | -856.71K | -299.35K | -253.16K | -359.80K | 0.00 | -9.27K | -788.53K | 35.91K | -543.60K | -3.62M | 89.52K | 3.51M | 246.23K | 91.17K | 256.18K | 39.45K | 248.46K | -63.84K | -53.20K | -369.81K |
| Net Income | -12.02M | -11.75M | -7.13M | -7.08M | -6.29M | -6.43M | -5.46M | -8.40M | -8.46M | -8.81M | -10.13M | -9.35M | -5.29M | 910.00K | -9.34M | -9.72M | -5.46M | -1.67M | -5.42M | -7.53M | -6.89M | -4.33M | -8.82M | -3.39M | -2.44M |
| Net Income Ratio | -156.78% | -113.56% | -104.95% | -5,870.91% | -751.29% | -25,253.91% | -2,887.06% | -1,620.78% | -1,025.84% | -437.90% | -221.84% | -276.84% | -46.66% | 4.98% | -95.77% | -145.69% | -34.68% | -12.11% | -54.74% | -79.54% | -182.11% | -46.69% | -67.33% | -60.19% | -60.71% |
| EPS | -0.09 | -0.12 | -0.08 | -0.08 | -0.15 | -0.23 | -0.22 | -0.40 | -0.49 | -0.82 | -1.76 | -0.02 | -0.01 | 0.00 | -0.02 | -0.02 | -0.01 | 0.00 | -0.01 | -0.02 | -0.02 | -0.02 | -0.03 | -0.01 | 0.00 |
| EPS Diluted | -0.09 | -0.12 | -0.08 | -0.08 | -0.15 | -0.23 | -0.22 | -0.40 | -0.49 | -0.82 | -1.76 | -0.02 | -0.01 | 0.00 | -0.02 | -0.02 | -0.01 | 0.00 | -0.01 | -0.02 | -0.02 | -0.02 | -0.03 | -0.01 | 0.00 |
| Weighted Avg Shares Out | 132.22M | 101.38M | 92.20M | 85.44M | 41.55M | 28.24M | 24.35M | 21.22M | 17.15M | 10.73M | 5.75M | 505.81M | 493.29M | 433.51M | 408.18M | 400.61M | 388.28M | 388.28M | 388.27M | 337.78M | 297.65M | 280.22M | 278.31M | 237.36M | 2.82B |
| Weighted Avg Shares Out (Dil) | 132.22M | 101.38M | 92.20M | 85.44M | 41.55M | 28.24M | 24.35M | 21.22M | 17.15M | 10.73M | 5.75M | 505.81M | 493.29M | 433.51M | 408.18M | 400.61M | 388.28M | 388.28M | 388.27M | 337.78M | 297.65M | 280.22M | 278.31M | 237.36M | 2.82B |
Source: https://incomestatements.info
Category: Stock Reports